Inovio Pharmaceuticals (INO) investor relations material

Executive summary

• FDA review of INO-3107 for RRP is advancing, with all scheduled inspections completed and a PDUFA target date of October 30, 2026; commercial launch preparations are underway, including partnerships with Syneos Health and other vendors.

• INO-3107 is positioned as a differentiated, patient-centric treatment aiming to become the new standard of care and reduce the need for surgery in RRP patients.

• Pipeline progress includes positive Phase 3 data for VGX-3100 in China and promising preclinical results for next-generation DNA-encoded monoclonal antibody and DPROT programs targeting rare diseases.

• Company operates as a single segment focused on DNA medicines for HPV, cancer, and infectious diseases, with the majority of resources allocated to INO-3107 development.

• Accumulated deficit was $1.8 billion as of June 30, 2026, with continued operating losses expected.

Financial highlights

• Ended Q2 2026 with $36.7 million in cash, cash equivalents, and short-term investments, down from $58.5 million at year-end 2025; excludes $18.3 million raised in July 2026 public offering.

• Net loss for Q2 2026 was $6.0 million ($0.07 per share), a significant improvement from $23.5 million ($0.61 per share) in Q2 2025, mainly due to a non-cash gain on warrant liabilities.

• Operating expenses for Q2 2026 were $18.6 million, down 19% year-over-year; six-month operating expenses were $40.6 million, down 16%.

• No revenue recognized in Q2 2026; $65,000 revenue in H1 2025 from collaborations.

• Significant non-cash gain of $18.0 million in H1 2026 from decrease in fair value of warrant liabilities.

Outlook and guidance

• Cash runway, including July 2026 offering proceeds, is expected to extend into late Q1 2027, supporting anticipated launch and pre-launch expenses for INO-3107.

• No additional capital raise anticipated before PDUFA; additional financing will be required beyond Q1 2027 to fund operations and commercialization if approved.

• Label negotiations with FDA for INO-3107 anticipated in September 2026; awaiting FDA feedback on confirmatory trial protocol.